Using the xenograft model of human psoriasis mentioned above, they demonstrated that blocking IFN-α signaling by administering neutralizing anti-IFN-α/β receptor antibodies or inhibiting the ability of pDCs to produce IFN-α by injecting anti-BDCA-2 monoclonal antibodies (mAbs) prevented the development of psoriasis [18]. This evidence concerns the gene IFNA2 and psoriasis.